Turns out, quite a lot. Real people, real labs, real science, all in service of the medicines that reach real patients. 💙
Ipsen
Фармацевтичне виробництво
Paris, Île-de-France 323 805 послідовників
Про нас
We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in 88 countries. For more information, visit ipsen.com. Pauta exclusiva para México: Clave de Autorización COFEPRIS: 243300201B1962 CONSULTE A SU MÉDICO.
- Вебсайт
-
http://www.ipsen.com
Зовнішнє посилання для Ipsen
- Галузь
- Фармацевтичне виробництво
- Розмір компанії
- 5 001-10 000 працівників
- Штаб-квартира
- Paris, Île-de-France
- Тип
- Публічна компанія
- Спеціалізації
- Pharmaceuticals, Specialty care: oncology, neuroscience, endocrinology, Research: peptides, toxins і Primary Care
Регіони
Працівники у Ipsen
Оновлення
-
Both. Because one without the other is just potential. At Ipsen, individual talent isn't asked to shrink for the team. And the team doesn't wait for one person to have all the answers. We bring distinct expertise together and let collective intelligence do what no single mind can. Your brilliance gets further here. Because it never works alone. This is Ipsen. Make a real impact, every day.
-
What job puts a molecule through its paces before it can become a medicine? Meet Ian Fox, CPD Principal Chemist focused on new asset development. He's the test driver (🏎️) every new molecule needs. Ian takes early-stage research (🧪) and figures out whether it can survive the real world, evaluating how it's made, how it can be manufactured consistently at scale, and how it can become the reliable, high-quality treatment patients need (💊). From the first lap to the finish line, glad to have you at the wheel, Ian. 💙 Learn more about Ian : https://lnkd.in/dFkZNgvJ
-
“The first half of the year has been a real game-changer for Ipsen.” Hear from our CEO, David Loew on Ipsen's excellent H1 2026 performance, progress across the pipeline, strategic business development milestones, and the upgraded outlook for the year ahead. Read more: https://lnkd.in/dJ5zbb4E
-
Ipsen delivered an excellent first half in 2026, with: ✅ 23.5% sales growth at constant exchange rates ✅ Double-digit growth across Oncology, Rare Disease and Neuroscience ✅ Significant pipeline delivery, including multiple positive Phase III readouts ✅ Strategic acquisitions to further strengthen the pipeline Based on this strong momentum and performance across the business, Ipsen has upgraded its full-year guidance. Read the full press release: https://lnkd.in/dhCkDUyP
-
-
For patients still waiting, we can't just imagine better medicines. We have to build them. Our teams ask what's missing, then build what's next. Curious enough to keep looking, innovative enough to keep delivering. That's how ideas become impact. This is Ipsen. Make a real impact, every day. Learn more: https://lnkd.in/e5SmJaiU
-
She knows exactly who her work is for. Because she's one of them. Rajminder Malhi is a Senior Customer Engagement Manager at Ipsen UK. She's also a patient. And after years of failed treatments that left her bed-bound, the right one gave her back the things most people take for granted: leaving the house, hugging her child. Now, every digital touchpoint she works on lands differently. Because she knows there's someone on the other end of it waiting for the same change she got. 💙 Learn more about Rajminder's story : https://lnkd.in/e5MrWaXH
-
Patients waiting for new medicines don't have time for hype cycles. The increasing complexity of modern science is the real reason pharma is talking about AI… but not every conversation is honest about what it can and can't yet do. So instead of claiming what AI will revolutionize, we're putting it to the experiment. A pilot with Claude for Healthcare & Life Sciences. Specialized AI built for scientific work, with governance and data protection built in from the start. We'll publish what we find. The good and the bad. Because patients deserve transparency, not empty promises. 💙 Learn more : https://lnkd.in/e2x5KpPz
-
We are pleased to complete the acquisition of Memo Therapeutics AG, further strengthening Ipsen's Rare Disease pipeline. This milestone reflects our commitment to advancing innovative medicines for patients with high unmet medical needs. Read more: https://lnkd.in/e2n4GBT7
-
-
What job fits this equation? 🧬 + 🔬 = 🚫 Meet Lindsey Rodrigues, Associate Director, Biological Sciences. A cancer biologist, she focuses on the hidden drivers of disease. At Ipsen, she leads early epigenetics research into how gene (🧬) activity shapes how cancer grows. Her work: spot which genes make a tumor tick (🔬), then design medicines to switch those genes off (🚫). Beyond the lab, she backs new ideas and mentors young scientists, believing every project should be one she’d trust for someone she loves. Grateful you’re on the team, Lindsey! Learn more about Lindsey : https://lnkd.in/eh6d5spX
-